A phase II trial of tamoxifen and bortezomib in patients with recurrent malignant gliomas
Crossref DOI link: https://doi.org/10.1007/s11060-015-1894-y
Published Online: 2015-08-19
Published Print: 2015-10
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Odia, Yazmín
Kreisl, Teri N.
Aregawi, Dawit
Innis, Ellen K.
Fine, Howard A.
Funding for this research was provided by:
National Cancer Institute (NCI) Intramural Research Program (NCT#00108069)
Text and Data Mining valid from 2015-08-19